Study question Does endometriosis compromise early embryonic development and/or clinical outcome in standard in vitro fertilization (sIVF) cycles? Summary answer Endometriosis does not compromise embryo development or clinical outcome in sIVF cycles characterised by normal semen parameters. What is known already IVF is an elective approach to overcome endometriosis-related infertility. The notion that IVF outcomes are altered in women with endometriosis the is scarce and conflicting. Different meta-analyses reached diverging conclusions concerning a possible impact of endometriosis on clinical outcome. With reference to laboratory outcomes, a reduced fertilization rate with sIVF was observed in several but not all studies. Study design, size, duration A retrospective analysis of 716 women undergoing their first sIVF cycles from 2015 to February 2021, 205 with in situ endometrioma (class IV) and 511 with tubal factor infertility. Participants/materials, setting, methods Diagnosis of endometriosis was based on ultrasound observation of cysts on at least two occasions at least two menstrual cycles apart. Women carrying atypical lesions, i.e., cysts with sonographic appearance compatible but not distinctive for endometriosis, were excluded. Multivariate analysis was conducted using the generalized estimating equation (GEE) approach, thus making it possible the analysis of variables with non-normal distribution. The primary study outcome was live birth rate. Main results and the role of chance After adjustment for maternal, paternal age, maternal body mass index (BMI), anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) we found no significant difference in fertilization rate [78,69 ± 26,16 (Endo) Vs 79,5 ± 24,01 (Tubal)], embryo quality [33,33 (0 – 57,86) endometriosis vs. 33,40 (0 – 67,70) tubal factor], blastulation rate [52,00 ± 15,01 (endometriosis) vs. 55,49 ± 14,98 (tubal factor)], top quality blastocyst [38,15 ± 18,67 (endometriosis) vs. 34,62 ± 14,77 (tubal factor)], ongoing pregnancy [OR = 0,84, 95% CI (0,54 – 1,32)], live birth [OR = 0,89, 95% CI (0,53 – 1,48)], and miscarriage rate [OR = 0,68, 95% CI (0,27 – 1,74)]. The only significantly different outcome was the percentage of embryos with ≥ 8 blastomeres on day 3 [25,00 (0 - 60,00) endometriosis Vs 40,00 (0 - 67,00) tubal factor]. Limitations, reasons for caution The retrospective design of the study and lack of data on cumulative live birth rates are additional limitations. Wider implications of the findings The results of our study suggest that in women with endometriosis fertilization rate, embryo quality, blastulation rate and live birth rate are not affected in sIVF cycles. Trial registration number N.A.

中文翻译：

---

P-309 子宫内膜异位症不会影响早期胚胎发育和活产：对 716 个标准体外受精周期的回顾性分析

研究问题 子宫内膜异位症是否会影响标准体外受精 (sIVF) 周期中的早期胚胎发育和/或临床结果？摘要答案子宫内膜异位症不会影响以正常精液参数为特征的 sIVF 周期中的胚胎发育或临床结果。众所周知，IVF 是一种克服子宫内膜异位症相关不孕症的选择性方法。在患有子宫内膜异位症的女性中，体外受精结果发生改变的观点是稀缺且相互矛盾的。关于子宫内膜异位症对临床结果的可能影响，不同的荟萃分析得出了不同的结论。参考实验室结果，在几项但不是所有研究中观察到 sIVF 的受精率降低。研究设计，大小，持续时间 对 2015 年至 2021 年 2 月接受第一个 sIVF 周期的 716 名女性进行回顾性分析，其中 205 名患有原位子宫内膜异位症（IV 类）和 511 名患有输卵管因素不孕症。参与者/材料、设置、方法子宫内膜异位症的诊断是基于至少两次相隔至少两个月经周期的囊肿的超声观察。携带非典型病变的女性被排除在外，即超声外观与子宫内膜异位症相符但不具有特征性的囊肿。使用广义估计方程（GEE）方法进行多变量分析，从而使非正态分布变量的分析成为可能。主要研究结果是活产率。主要结果和机会的作用在对母亲、父亲年龄、母亲体重指数（BMI）进行调整后，抗苗勒管激素 (AMH) 和促卵泡激素 (FSH) 我们发现受精率 [78,69 ± 26,16 (Endo) Vs 79,5 ± 24,01 (Tubal)]、胚胎质量 [33] 没有显着差异,33 (0 – 57,86) 子宫内膜异位症 vs. 33,40 (0 – 67,70) 输卵管因子]，囊胚率 [52,00 ± 15,01 (子宫内膜异位症) vs. 55,49 ± 14,98 (输卵管因素）]，优质囊胚 [38,15 ± 18,67（子宫内膜异位症）与 34,62 ± 14,77（输卵管因素）]，持续妊娠 [OR = 0,84, 95% CI (0,54 – 1,32)]、活产 [OR = 0,89, 95% CI (0,53 – 1,48)] 和流产率 [OR = 0,68, 95% CI (0,27 – 1,74) )]。唯一显着不同的结果是第 3 天具有 ≥ 8 个卵裂球的胚胎百分比 [25,00 (0 - 60,00) 子宫内膜异位症与 40,00 (0 - 67,00) 输卵管因子]。限制，谨慎的理由 该研究的回顾性设计和缺乏累积活产率数据是额外的限制。研究结果的更广泛意义 我们的研究结果表明，子宫内膜异位症女性的受精率、胚胎质量、囊胚率和活产率在 sIVF 周期中不受影响。试用注册号 NA